More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$8.90B
EPS
-3.71
P/E ratio
--
Price to sales
2.05
Dividend yield
--
Beta
1.456346
Previous close
$188.47
Today's open
$188.94
Day's range
$184.64 - $190
52 week range
$143.06 - $228.88
show more
CEO
James C. Foster
Employees
19700
Headquarters
Wilmington, MA
Exchange
New York Stock Exchange
Shares outstanding
48167730
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
LH vs. CRL: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?
Zacks Investment Research • Jun 15, 2026

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Jun 3, 2026

Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Sidoti Small-Cap Virtual Conference on June 17 and 18, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 10:00 a.m. EDT on Wednesday, June 17. A live webcast will be available on the Company's investor relations website. An archived replay will be avai.
Business Wire • Jun 3, 2026

Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Seeking Alpha • Jun 2, 2026

Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.
Business Wire • Jun 1, 2026

Charles River Associates (CRA) to Present at Noble Capital Markets Virtual Conference
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Noble Capital Markets Virtual Equity Conference on June 3 and 4, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 11:00 a.m. EDT on Wednesday, June 3. A live webcast will be available on the Company's investor relations website. An archived replay wil.
Business Wire • May 26, 2026

Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • May 20, 2026

Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting i.
Business Wire • May 13, 2026

Charles River (CRL) Reliance on International Sales: What Investors Need to Know
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Zacks Investment Research • May 11, 2026

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.
Business Wire • May 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Charles River Laboratories International Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.